HCC Biomarkers
AFP-L3 and DCP
μTASWako® i30
Automated Platform
microfluidic-based clinical immunoanalyzer
The μTASWako i30 is a commercially available microfluidic-based clinical immunoanalyzer for in vitro diagnostic use in the USA. The microfluidic technology minimizes instrument hands-on time while maximizing efficiency through integration and automation of clinical laboratory processes.
For several years the biomarker AFP has been used as a tool in the diagnosis of HCC. However, AFP results are often not definitive until a tumor has reached a large size or an advanced state. Recently, related biomarkers called AFP-L3 and DCP have been shown to help rule out HCC in cases where AFP values alone are ambiguous. Separation methods involving microfluidic-based separation are performed on Wako's proprietary μTASWako® i30 instrument incorporating elements which allow automated measurement of these valuable cancer biomarkers.
Performance through technology
Speed, precision and sensitivity
- Nine minutes to first result, two minutes per subsequent result
- Throughput: 25 results per hour
- Superb analytical sensitivity
- Accurate and precise performance
Optimized workflow design
Efficiency and productivity
- Up to six analyte measurements per sample
- Random assay selection per sample
- Short setup time - 10 minutes
- Two-hour walk away time
- Automated calibration and quality control
- STAT capability
- LIS integration capability
- RFID tag enabled reagent tracking
Easy to use
Convenience and automation
- Ready to use reagents
- Intuitive touch panel operation
- On-board refrigerated reagents
- Easy access to consumables and waste
- Minimal routine maintenance
- Download "μTASWako i30 Brochure" (pdf)
